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Abstract 
Extraosseous  Ewing’s  sarcoma  (EES)
involving the central nervous system is rare,
but can be diagnosed and distinguished from
other  primitive  neuroectodermal  tumors
(PNET) by identification of the chromosomal
translocation (11;22)(q24;q12). We report EES
arising  from  the  spinal  intradural
extramedullary  space,  based  on  imaging,
histopathological, and molecular data in two
men, ages 50 and 60 years old and a review of
the  literature  using  PubMed  (1970-2009).
Reverse transcriptase polymerase chain reac-
tion  (RT-PCR)  identified  the  fusion  product
FL1-EWS. Multimodal therapy, including radia-
tion and alternating chemotherapy including
vincristine,  cyclophosphamide,  doxorubicin
and ifosfamide and etoposide led to local tumor
control  and  an  initial,  favorable  therapeutic
response. No systemic involvement was seen
from the time of diagnosis to the time of last
follow-up (26 months) or death (4 years). This
report confirms that EES is not confined to the
earliest decades of life, and like its rare occur-
rence as an extra-axial meningeal based mass
intracranially, can occasionally present as an
intradural  mass  in  the  spinal  canal  without
evidence of systemic tumor.  Gross total resec-
tion followed by multimodal therapy may pro-
vide for extended progression free and overall
survival.
Introduction
Extraosseous  Ewing’s  Sarcoma  (EES)  is  a
rare tumor of neuroectodermal origin, belong-
ing to the Ewing’s family of tumors.  Historically,
the characteristic small, round, blue cells with
glycogen  and  a  lack  of  cytoplasmic  filaments
were diagnostic.1 In 1992, diagnostic accuracy
was improved by identification of a tumor spe-
cific  chimeric  gene  with  the  chromosomal
translocation  (11;22)(q24;q12)  occurring  in
85% of cases.2 The fusion product that results,
most commonly EWS-FLI1, is thought to act as
an aberrant transcription factor.3,4
Ewing’s sarcoma limited to the central nerv-
ous system is especially rare.  In the study of
2792  patients  registered  in  three  Intergroup
Rhabdomyosarcoma Study clinical trials (1972-
1991),  130  patients  thought  to  have  rhab-
domyosarcoma were found on pathology review
to have extraosseous Ewing’s sarcoma and none
had Ewing’s sarcoma affecting the spinal canal
or its contents.3 The most commonly affected
body  regions  were  trunk  (32%,  including
paraspinal, chest and abdominal wall), extremi-
ty (26%), head and neck (18%, including orbit).
Consequently, nervous system involvement may
rarely occur by compression via extension from
a primary trunk or head and neck mass. There
have  been  occasional  reports  where  nervous
system involvement occurs as a result of com-
pression from a primary spinal epidural lesion,
or a dural based mass intracranially. Few cases
of spinal intradural EES have been previously
reported.5-10 Given  the  paucity  of  information
available  in  that  literature  on  treatment  and
outcomes in this rare circumstance, we report
two  middle-aged  men  with  molecularly-diag-
nosed spinal intradural extramedullary EES and
no concurrent or late metastatic involvement
outside of the nervous system. 
Case #1
A 60-year-old gentleman had lower back pain
which radiated to both ankles for two months.
There was accompanying numbness in the lat-
eral thigh but no weakness. MRI demonstrated
a sausage-shaped, 3.3-cm, inhomogeneous T2-
hyperintense, gadolinium-enhancing lesion in
the L2-3 interspace. 
Meningioma was suspected. There was no
prior history of malignancy.  Intraoperatively,
the tumor appeared to arise from the lumbar
nerve root, distinct from the arachnoid mater.
It  was  friable,  vascular,  and  bled  easily.
Subtotal  resection  was  performed  in  an
attempt to spare the lumbar nerve root.  
Histopathologic  examination  showed  a
monomorphic  population  of  medium-sized
cells in sheets and slightly cohesive nests. The
nuclei  of  neoplastic  cells  showed  fine  chro-
matin and frequent mitotic figures. There was
intense membranous immunostaining of the
neoplastic  cells  with  CD99  and  diffuse  cyto-
plasmic immunopositivity of CD56. Immuno  -
histochemistry  further  showed  positive
expression  of  MIC2,  CAM5.2,  synaptophysin,
and vimetin and was negative for markers of
hematolymphoid  neoplasm,  including  CD3,
CD43, and CD20. Reverse transcriptase poly-
merase chain reaction (RT-PCR) identified the
fusion product FL1-EWS, making the diagnosis
of extraosseous Ewing’s Sarcoma (Figure 1). 
Evaluation  by  body  positron  emission
tomography (PET) scan did not show tumor
elsewhere.  
He  received  two  cycles  of  ifosfamide  and
etoposide alternating with two cycles of ifos-
famide and doxorubicin prior to radiotherapy
(5040 cGy in 28 fractions) to L1 through L4.11
Following radiation, he then received alternat-
ing cycles of this same chemotherapeutic reg-
imen. Seven months following the completion
of radiotherapy, there was no visible remain-
ing  tumor  at  the  original  site  upon  repeat
imaging, but a new T2 hyperintense, gadolini-
um-enhancing  1.1  cm  intradural  lesion  was
seen  at  the  S2-3  level.  There  was  also  pre-
sumed tumor in lumbar cul de sac, dorsal to
the L5 to S2 vertebral bodies (Figure 2a). Fine
needle  aspiration  specimen  demonstrated
recurrence. He received 5940 cGy in 33 frac-
tions to the lumbosacral spine and adjuvant
oral temozolomide for 3 months.  Imaging per-
formed  two  months  following  radiotherapy
demonstrated  a  complete  response.  Five
months later, he developed saddle anesthesia,
foot  drop,  and  asymmetric  lower  extremity
numbness. Widespread leptomeningeal metas-
tases were seen at the original L2-3 site, in the
cervical  and  midthoracic  regions,  as  well  as
intracranially, predominantly involving the 4th
ventricle..  
There was no evidence of intraparenchymal
involvement or hydrocephalus.  Given his pre-
vious  response  to  therapy,  he  received  3500
cGy, in 14 fractions to the neuraxis above the
prior RT fields, with boosts of 500-1000 cGy in
2-4 fractions to regions with gross disease fol-
lowed by three cycles of adjuvant vincristine,
doxorubicin,  and  cyclophosphamide.  Again,
imaging demonstrated a complete response. 
He remained symptom and disease free for
8  months  until  he  developed  progressive,
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symptomatic disease of the cauda equina and
received additional radiation, 3000 cGy, in 15
fractions, to the involved region of the lumbar
spine. Ten months after reirradiation to the
lumbar spine, he again developed symptomatic
progression, but with severe deficits including
saddle anesthesia, paraplegia, and urinary and
fecal incontinence. MRI revealed tumor involv-
ing the dura at the level of L2 without evidence
of compression of the conus or cauda equina.
He  received  2500  cGy  in  5  fractions  using
stereotactic technique, followed by oral etopo-
side, with minor response to etoposide in the
non-irradiated  sites.  However,  within  two
months he developed widespread intracranial
and  spinal  leptomeningeal  disease.  He  died
with diffuse disease limited to the nervous sys-
tem, without evidence of systemic malignancy,
48 months after his initial diagnosis.    
Case #2
A  50-year-old  man  had  insidious  onset  of
asymmetric hip and low back pain that radiated
into the lower extremities. Within four months,
he developed weakness and numbness in the
medial thighs and groin. He required a wheel-
chair, and was no longer able to urinate or defe-
cate.  Examination revealed asymmetric, pre-
dominantly proximal weakness; increased ten-
don jerks in the lower extremities; and mute
plantar responses.  Sensory loss to vibration
and proprioception was profound in both lower
extremities,  with  an  L1-sensory  level  to  pin-
prick and temperature.    
A T2-hyperintense, contrast-enhancing mass
with areas of cystic degeneration was identi-
fied  in  the  T10-L1  extramedullary  intradural
space on MRI (Figure 3). This was completely
resected.  
Neoplastic cells were positive for pancytoker-
atin (AE1/AE3), OSCAR, CAM 5.2, MIC-2, CD56,
and  synaptophysin  and  negative  for  LCA
(CD45),  S100,  chromogranin,  and  GFAP.
Reverse transcriptase polymerase chain reac-
tion (RT-PCR) for the fusion gene EWSR1-FLI1
was  positive.  The  EWSR1-ERG  RT-PCR  was
negative (Figure 4). 
Staging  evaluation,  including  whole  body
FDG-positron emission tomography, was nega-
tive for tumor elsewhere.  
He received one cycle of VCD followed by IE
for two cycles and adjuvant radiation to the
thoracolumbar spine (5040Gy, 28f).  Twenty six
months following diagnosis, he remains stable
with no recurrence. 
Literature search
An  additional  search  for  all  cases  of
intradural  extramedullary  extra-osseous
Ewing’s sarcoma of the spinal cord was per-
formed  using  PubMed  for  the  timeframe
January 1970 to December 2009. Cases were
analysed  for  basic  demographic  features
Case Report
Figure 2. Case #1 – Lumbar MRI: Widespread
spinal leptomeningeal involvement, shown on
both  fast-spin  echo  T2  (A)  and  T1  with
gadolinium contrast enhancement (B). 
Figure 3. Case #2 – Lumbar MRI, Fast-spine
echo T2 (A) and T1 with gadolinium contrast
(B), demonstrating a heterogeneous, enhancing
sausage shaped intradural extramedullary tumor.
Figure 1. Sheets of small round cells with uniform, round to oval vesicular nuclei, fine-
ly  stippled  chromatin,  and  indistinct  nucleoli  (A)  (high  power  -  60X;  H&E  stain).
Membranous immunostaining of the neoplastic cells for CD99 (B) (high power - 60x).
Strong diffuse cytoplasmic immunopositivity in the neoplastic cells (high power - 60x)






F[Rare Tumors 2011; 3:e7] [page 23]
including (age and sex), method of diagnosis
(molecular  and/or  histopathologic),  presence
of metastasis outside of the central nervous
system, and survival time (months) (Table 1).
Discussion
When EES involves the central nervous sys-
tem, it usually does so via the epidural space,
either as a direct extension of a primary epidur-
al lesion, or more commonly from metastatic
bone disease.  We are aware of only seven pre-
viously reported cases with disease presenting
in and limited to the spinal intradural space.
Molecular  diagnosis,  confirming  the  fusion
product (11;22)(q24;q12), was demonstrated in
only a subset of these. Reported survival is vari-
able, at 4 to more than 30 months. Notably, our
patients were both in late adulthood upon pres-
entation, confirming that EES is not limited to
patients in the earliest decades of life, and with
aggressive multimodal therapy, one is alive with
no evidence of disease at 26 months, and the
other, despite subtotal resection initially, lived
48 months.  
Pathologically,  the  differential  diagnosis  of
EES  includes  all  other  small  round  blue  cell
tumors: lymphoblastic lymphoma, desmoplastic
small  round  cell  tumor,  rhabdomyosarcoma,
neuroblastoma, primary central nervous system
primitive  neuroectodermal  tumors,  and  small
cell carcinoma.  While distinguishable clinically
as all of these entities in the intradural space
would be metastatic and not a primary process,
the pathological diagnosis, especially on mor-
phologic  grounds,  can  be  difficult.  Moreover,
both EES and primary central nervous system
primitive  neuroectodermal  tumors  are  desig-
nated PNET and stain for neuroendocrine mark-
ers. While vimentin, S100, CD99/MIC2 (in 84%
to 100% of cases) as well as neuroendocrine
markers  including  CD56  and  synaptophysin
may  or  may  not  be  helpful  in  distinguishing
these entities, the reverse transcriptase poly-
merase chain reaction (RT-PCR) for the fusion
gene  EWSR1-FTI1  is  diagnostic.  Additional
markers, including those derived from muscle
(myogenin, muscle specific actin, MyoD1) and
the hematolymphoid system (CD3, CD34, TdT),
are strategic in ruling out other small blue cell
tumors and ultimately help confirm the diagno-
sis of EES.  
In the management of Ewing’s sarcoma, com-
plete resection of the primary lesion is associat-
ed with superior outcomes.1,3 It is noteworthy
that the surgical approach toward other diag-
nostic  possibilities  for  similar  appearing
intraspinal lesions also requires an attempt at
complete resection: meningioma, schwannoma,
myxopapillary  ependymoma,  paraganglioma,
hemangioblastoma,  and  metastasis.12
Therefore, surgical planning for a gross total
resection, where possible, when such lesions
are encountered, may improve outcomes for the
rare patient who presents with EES involving
the intradural extramedullary spinal canal.  
Our  patients  had  a  favorable  therapeutic
response  to  multimodal  therapy  at  treatment
initiation, including radiation and alternating
Case Report
Table 1. Published cases of spinal intradural extraosseous Ewing’s sarcoma.
Age/Sex  Location  Metastasis after Post-operative Clinical
of mass initial presentation treatment outcome
11F5  C7-T1 Not reported Subtotal  Not reported
resection only
10M6 T11-T12, L3-5  Not reported Chemoradiation Dead of disease 
at 4 months
166 L2-3, T4-6  Lung, brain, Chemoradiation Dead of disease 
CSF at 5 months
26M7 T11-S2 T6-7 50 Gy, 25 fx Survival reported 
Alternating VCD and  at 6 months
ICE (6 cycles)*
21M8 T10-11 confirmed  L1-2 3780Gy, 21 fx Survival reported 
t(11;22)(q24;q12) VCD (5 cycles); at 30 months
IE (2 cycles)
28M9 T12-L3 Yes  Resection only Fatal metastatic  
Location not specified disease by 9 months
11M10 C4-T2 Not reported  Protocol: Not reported
Euro-EWING-99
*Treatment was extended after metastases were found. fx, fractions; ICE, ifosfamide, cisplatin, etoposide; VCD, vincristine, cyclophosphamide, doxorubicin.
Figure 4. High-power appearance of uniform round nuclei and indistinct cytoplasmic
borders (A) (60x; H&E stain). Sparse and focal cytoplasmic immunopositivity of pancy-
tokeratin  (B)  (AE1/3;  60x).  Diffuse  and  strong  cytoplasmic  immunoreactivity  of
OSCAR-keratin (C) (60x), and CAM 5.2 (D) (60x) respectively. CD99 membranous
immunostaining of the neoplastic cells (E) (high power - 60x). Strong diffuse cytoplas-
mic immunopositivity of CD56 (neuroendocrine marker) in the neoplastic cells (F)






F[page 24] [Rare Tumors 2011; 3:e7]
cycles  of  Vincristine,  Cyclophosphamide,  and
Doxorubicin  (VCD)  and  Ifosfamide  and
Etoposide  (IE).    This  is  consistent  with  our
unreported institutional experience of molecu-
larly-diagnosed  EES  in  any  location,  treated
with alternating cycles of VCD and IE.  In a
series of 18 patients at Mayo Clinic with molec-
ularly-diagnosed EES, in any location, alternat-
ing cycles of VCD and IE led to a complete tumor
response in 83% (15/18) and a partial response
in  11%  (2/18)  with  a  mean  survival  of  40
months  (personal  communication,  A.  Bardia,
unpublished data). 
One of our cases demonstrated the propensi-
ty  for  intraspinal  EES  to  recur  with  lep-
tomeningeal  dissemination,  suggesting  that
craniospinal axis radiation may be necessary
for  long-term  disease  control.  In  previously
reported cases, only Bouffet et al. provide suffi-
cient follow-up data to determine whether this
has been previously encountered.6 In one of the
two patients described in that report, metastasis
was  limited  to  the  intrathecal  space.  In  our
patients, there has not been recurrence outside
of the central nervous system. However, the sec-
ond patient reported by Bouffet et al developed
metastasis in the lung suggesting that over the
long term, patterns of failure in this presenta-
tion  of  EES  include  locations  outside  of  the
nervous system.  
Conclusions
EES may occur as late as the 6th decade. Like
its rare occurrence as an extra-axial meningeal
or dural based mass intracranially, or primary
epidural spinal mass, it can occasionally present
as an intradural mass in the spinal canal with-
out  evidence  of  systemic  involvement.  Gross
total resection followed by multimodal therapy
may provide for extended progression free and
overall survival. With subtotal resection, cran-
iospinal axis radiation could be considered to
avert diffuse meningeal dissemination, but the
use of this approach merits careful assessment
of potential toxicities, and should be carefully
considered on a patient-by-patient basis.
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